Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Acquired Hemophilia
Acquired Hemophilia
  • Overview
  • Diagnosing
  • Clinical Pathway

Diagnosing acquired hemophilia

When unexplained bleeding with no previous history occurs, urgent laboratory testing to aid in diagnosis is recommended. Approximately 70% of acquired hemophilia (AH) patients experience severe, unexplained bleeding at diagnosis, with widely varying bleeding patterns.1

Diagnosing acquired hemophilia

When unexplained bleeding with no previous history occurs, urgent laboratory testing to aid in diagnosis is recommended. Approximately 70% of acquired hemophilia (AH) patients experience severe, unexplained bleeding at diagnosis, with widely varying bleeding patterns.1

How do patients with AH present?

Acquired hemophilia signs and symptoms


Purpura (bruising) and soft-tissue hemorrhage2

Bleeding sites atypical of congenital hemophilia3

Gastrointestinal, urological, or retroperitoneal bleeding4,5

Prolonged bleeding following surgery2

Compartment syndrome (compression of blood vessels and nerves)3

Isolated prolonged activated partial thromboplastin time (aPTT)2

Purpura (bruising) and soft-tissue hemorrhage2

Bleeding sites atypical of congenital hemophilia3

Gastrointestinal, urological, or retroperitoneal bleeding4,5

Prolonged bleeding following surgery2

Compartment syndrome (compression of blood vessels and nerves)3

Isolated prolonged activated partial thromboplastin time (aPTT)2

Significant dark bruising along patient’s chest and abdomen
Signficant dark bruising along patient’s back and left hip

Importance of early diagnosis

Patients frequently experience delays in diagnosis for acquired hemophilia. Prompt diagnosis is vital to minimize a patient’s risk of bleeding complications and avoid non-essential invasive procedures.2

  
  Parameter

 
Parameter

Normal
range7,a

  
Normal range6,a

Acquired
hemophilia6

Acquired
hemophilia3

aPTT

25-38
seconds

25-38 seconds

Above
normal

Above normal

PT

11-13
seconds

11-13 seconds

Normal

Normal

FVIII

50%-150%
activity

50%-150% activity

Below
normal

Below normal

aPTT=activated partial thromboplastin time; PT=prothrombin time.
aNormal ranges may vary among different laboratories.

Consult a hematologist immediately if lab results show an unexplained, isolated, prolonged aPTT.3,4,7

Consult a hematologist immediately if lab results show an unexplained, isolated, prolonged aPTT.4,6

Confirm an acquired hemophilia diagnosis through lab testing

Flowchart showing steps used to confirm an acquired hemophilia diagnosis through lab testing
Flowchart showing steps used to confirm an acquired hemophilia diagnosis through lab testing

Explore an interactive clinical pathway for patients with acquired hemophilia

Review an example of treating acquired hemophilia in the emergency department.

Go to clinical pathway
Pathway icon

References:

  1. Knoebl P, Marco P, Baudo F, et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.
  2. Collins PW, Percy CL. Advances in the understanding of acquired haemophilia A: implications for clinical practice. Br J Haematol. 2010;148(2):183-194.
  3. Giangrande P. Acquired Hemophilia: Revised Edition: Treatment of Hemophilia No. 38. Montréal, Québec: World Federation of Hemophilia; 2012:1-2.
  4. Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1-16.
  5. Collins PW, Hirsch S, Baglin TP, et al; for UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870-1877.
  6. Introduction to normal values (reference ranges). In: Wallach J, ed. Interpretation of Diagnostic Tests. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:3-25.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US23HCP00056 August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials